Orthocell Limited
Research Orthocell Limited (OCC.AX) on Bullrun: market cap AUD 182.50M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOCC.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 182.50M
- Financial periodFY2026
- RevenueAUD 11.41M
- Revenue growth51.1%
- Net income-AUD 13.91M
- Free cash flow-AUD 14.01M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 182.50M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 11.41M | -AUD 13.91M | -AUD 14.01M | 100.0% | -0.05 | AUD 43.95M | AUD 970.19K | AUD 34.41M |
| FY2025 | AUD 7.55M | -AUD 8.57M | -AUD 9.04M | 63.6% | -0.04 | AUD 28.62M | AUD 576.90K | AUD 14.57M |
| FY2024 | AUD 5.32M | -AUD 7.18M | -AUD 7.45M | 69.4% | -0.04 | AUD 20.61M | AUD 689.69K | AUD 4.53M |
| FY2023 | AUD 4.24M | -AUD 6.25M | AUD 13.96M | 75.8% | -0.03 | AUD 24.82M | AUD 562.31K | AUD 6.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 182.50M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Orthocell Limited
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Orthocell Limited's market cap?
Orthocell Limited's market capitalization is AUD 182.50M.
What does Orthocell Limited do?
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair.